New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
10:55 EDTARWR, ISISArrowhead weakness related to Isis' competing HBV program, says Piper Jaffray
Arrowhead Research (ARWR) shares are lower after competitor ISIS Pharmaceuticals (ISIS) announced preclinical data on its antisense compound targeting hepatitis B virus. Piper anticipates Arrowhead will begin multi-dose ARC-520 Phase II studies in Q4 and reiterates its Overweight rating and $24 price target on Arrowhead.
News For ARWR;ISIS From The Last 14 Days
Check below for free stories on ARWR;ISIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2014
11:42 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
August 19, 2014
10:42 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
August 18, 2014
10:57 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
August 15, 2014
10:41 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: ARWR ICPT UVXY MNKD KING VIX SVXY VXX RAX OPK
07:01 EDTISISIsis Pharmaceuticals earns $2M from advancement of ISIS-SMN from Biogen
Isis Pharmaceuticals (ISIS) announced that it has earned a $2M milestone payment from Biogen (BIIB) related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy.
August 14, 2014
11:46 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
August 13, 2014
10:33 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: RPTP ARWR ZU ICPT MNKD UBNT OLED RAX UVXY VNDA
10:20 EDTARWRHigh option volume stocks
Subscribe for More Information
09:15 EDTARWROn The Fly: Pre-market Movers
Subscribe for More Information
07:56 EDTARWRArrowhead should trade up on Hep B data, says RBC Capital
RBC Capital said Arrowhead's initial top-line Phase IIa data showed good knockdown of s-antigen, durability, and safety. The firm expects shares to trade up on the news and notes doctors say increased doses and time could lead to higher cures of Hep B. Shares are Outperform rated.
07:36 EDTARWRArrowhead shares recommended after ARC-520 data at Deutsche Bank
Subscribe for More Information
06:35 EDTARWRArrowhead shares likely weak on lack of data, says Piper Jaffray
Piper Jaffray expects shares of Arrowhead to be under pressure following the company's Q3 results given the lack of data for ARC-520 for the treatment of hepatitis-B virus infection. Piper keeps an Overweight rating on the stock with a $24 price target.
August 12, 2014
19:02 EDTARWROn The Fly: After Hours Movers
Subscribe for More Information
16:16 EDTARWRArrowhead Research provides update on phase 2a study of ARC-520
Arrowhead Research completed its dosing of 1mg/kg and 2mg/kg dose cohorts. The company's initial blinded data suggest that the magnitude of HBsAg knockdown is similar to non-human primate studies, including the chronically infected chimpanzee reported on previously. ARC-520 continues to be well tolerated, with no dropouts or serious adverse events reported. The overall rate of AEs has been lower in the phase 2a than in the phase 1 normal volunteer study and safety labs continue to show no indication of end organ toxicity. The company received IRB and DSMB approvals to proceed and began enrolling an additional dose cohort at 3 mg/kg in the Phase 2a patient study.
16:13 EDTARWRArrowhead Research reports Q3 EPS (22c), consensus (22c)
Total operating expenses for the quarter were $12.7M, compared to $6.4M for the quarter ended June 30, 2013. The company’s cash and investments of cash were $188.5M at June 30.
August 8, 2014
06:28 EDTARWRArrowhead Research volatility elevated
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use